Stefanie Mandl-Cashman
Chief Scientific Officer Indapta Therapeutics
Stefanie Mandl-Cashman, PhD, is Chief Scientific Officer at Indapta Therapeutics, where she leads the development of next-generation NK cell immunotherapies for cancer and other diseases. An accomplished immunology executive, she has extensive experience advancing innovative cell therapy platforms from discovery through IND submission and early clinical development. Her expertise spans NK cell biology, TCR-T therapies, cancer vaccines, bispecific antibodies, translational immunology, biomarker strategy, and IND-enabling research. Throughout her career, Stefanie has built high-performing R&D organizations and translated pioneering science into clinically and commercially impactful therapeutic programs.
Seminars
- Identifying critical quality attributes in starting material that correlate with expansion rates, cell viability and final product yield to minimize costly manufacturing failures
- Implementing upfront screening assays to characterize donor health status, cellular phenotype and functional markers before committing to full-scale production
- Leveraging characterization data to reduce time spent evaluating unsuitable donors and accelerate selection of high-performing material for consistent output
